In the phase IIB LUX-Lung 7 trial comparing afatinib and gefitinib as the first-line treatment for EGFR-mutated NSCLC patients, the researchers demonstrated that afatinib significantly improved PFS and time-to-treatment failure compared with gefitinib [38]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.